For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed the day trading at $73.57 up 0.79% from the previous closing price of $72.99. In other words, the price has increased by $0.79 from its previous closing price. On the day, 2.56 million shares were traded. IONS stock price reached its highest trading level at $74.04 during the session, while it also had its lowest trading level at $72.52.
Ratios:
For a better understanding of IONS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 16 ’25 when Swayze Eric sold 53 shares for $73.62 per share. The transaction valued at 3,902 led to the insider holds 256 shares of the business.
PARSHALL B LYNNE sold 5,000 shares of IONS for $358,722 on Oct 15 ’25. The Director now owns 61,344 shares after completing the transaction at $71.74 per share. On Oct 15 ’25, another insider, Devers Shannon L., who serves as the EVP, Chief Human Resources Ofc of the company, sold 6,000 shares for $72.94 each. As a result, the insider received 437,654 and left with 15,937 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 11726412800 and an Enterprise Value of 11417445376. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.42 while its Price-to-Book (P/B) ratio in mrq is 18.54. Its current Enterprise Value per Revenue stands at 12.094 whereas that against EBITDA is -44.744.
Stock Price History:
The Beta on a monthly basis for IONS is 0.34, which has changed by 0.8591442 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $74.42, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 18.40%, while the 200-Day Moving Average is calculated to be 76.64%.
Shares Statistics:
Over the past 3-months, IONS traded about 2.52M shares per day on average, while over the past 10 days, IONS traded about 1842180 shares per day. A total of 159.20M shares are outstanding, with a floating share count of 158.12M. Insiders hold about 0.80% of the company’s shares, while institutions hold 107.03% stake in the company. Shares short for IONS as of 1760486400 were 13699358 with a Short Ratio of 5.44, compared to 1757894400 on 11972594. Therefore, it implies a Short% of Shares Outstanding of 13699358 and a Short% of Float of 11.399999.
Earnings Estimates
. The current rating of Ionis Pharmaceuticals Inc (IONS) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.1, with high estimates of -$0.95 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$1.71 and -$2.49 for the fiscal current year, implying an average EPS of -$1.93. EPS for the following year is -$1.96, with 11.0 analysts recommending between -$0.46 and -$3.17.
Revenue Estimates
19 analysts predict $130.51M in revenue for. The current quarter. It ranges from a high estimate of $172.61M to a low estimate of $111.1M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 19 analysts are estimating revenue of $145.89M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $120.54M.
A total of 24 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $834.19M, resulting in an average revenue estimate of $866.53M. In the same quarter a year ago, actual revenue was $705MBased on 23 analysts’ estimates, the company’s revenue will be $899.14M in the next fiscal year. The high estimate is $1.15B and the low estimate is $681.53M.
